Last reviewed · How we verify

NCT07100457

OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury

Recruiting now Last updated 3 August 2025
What this trial tests

trial testing Blood Biomarker Profiling and Prognostic Follow-up in Myocardial Ischemia-Reperfusion Injury in 200 participants. Currently enrolling.

Timeline
1 September 2019
Primary endpoint
30 August 2027
30 August 2027

Quick facts

Lead sponsorSoutheast University, China
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date1 September 2019
Primary completion30 August 2027
Estimated completion30 August 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Southeast University, China

Who can join

Adults 18 to 90, any sex, with Myocardial Ischemia-Reperfusion Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Southeast University, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07100457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing